Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Are PARP inhibitors a new standard of care option for MBC patients?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.06.19
Views: 225

Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Jennifer Litton talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about using PARP inhibitors to treat metastatic breast cancer (MBC) and whether or not they can be considered a new standard of care option.

She explains that, although PARP inhibitors have been shown to be beneficial and could be considered a new standard of care, they are still not curing patients across the board.

This programme has been supported by an unrestricted educational grant from Pfizer.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation